Cargando…

Personalized radiation dosimetry for PRRT—how many scans are really required?

PURPOSE: Over recent years, peptide receptor radiotherapy (PRRT) has been recognized as an effective treatment for patients with metastatic neuroendocrine tumors (NETs). Personalized dosimetry can contribute to improve the outcome of peptide receptor radiotherapy (PRRT) in patients with metastatic N...

Descripción completa

Detalles Bibliográficos
Autores principales:	Freedman, Nanette, Sandström, Mattias, Kuten, Jonathan, Shtraus, Natan, Ospovat, Inna, Schlocker, Albert, Even-Sapir, Einat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214583/ https://www.ncbi.nlm.nih.gov/pubmed/32394075 http://dx.doi.org/10.1186/s40658-020-00293-z

Ejemplares similares

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression
por: Jahn, Ulrika, et al.
Publicado: (2023)

Kidney dosimetry in 777 patients during (177)Lu-DOTATATE therapy: aspects on extrapolations and measurement time points
por: Sandström, Mattias, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy (PRRT) with (177)Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms
por: Jahn, Ulrika, et al.
Publicado: (2021)

PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?
por: Haug, Alexander R.
Publicado: (2020)

Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours
por: Sandström, Mattias, et al.
Publicado: (2015)

[(68)Ga]Ga-PSMA-11 PET/CT for monitoring response to treatment in metastatic prostate cancer: is there any added value over standard follow-up?
por: Kuten, Jonathan, et al.
Publicado: (2019)

Post-PRRT scans: which scans to make and what to look for
por: Aalbersberg, Else A., et al.
Publicado: (2022)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT
por: Del Prete, Michela, et al.
Publicado: (2018)

The significance of equivocal bone findings in staging PSMA imaging in the preoperative setting: validation of the PSMA-RADS version 1.0
por: Kuten, Jonathan, et al.
Publicado: (2021)

68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy
por: Kesler, Mikhail, et al.
Publicado: (2021)

Counter-Point: Are We Really Ordering Too Many CT Scans?
por: Schwartz, David T.
Publicado: (2008)

Impact of dead time on quantitative (177)Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
por: Desy, Alessandro, et al.
Publicado: (2020)

Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT)
por: Chicheportiche, Alexandre, et al.
Publicado: (2018)

Head-to-head comparison of [(68)Ga]Ga-FAPI-04 and [(18)F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma
por: Kuten, Jonathan, et al.
Publicado: (2021)

How many dimensions are really compactified ?
por: Antoniadis, Ignatios
Publicado: (2005)

Combination Therapies with PRRT
por: Yordanova, Anna, et al.
Publicado: (2021)

The PRRT2 knockout mouse recapitulates the neurological diseases associated with PRRT2 mutations
por: Michetti, Caterina, et al.
Publicado: (2017)

PRRT: identikit of the perfect patient
por: Albertelli, M., et al.
Publicado: (2020)

Functional study and pathogenicity classification of PRRT2 missense variants in PRRT2‐related disorders
por: Zhao, Shao‐Yun, et al.
Publicado: (2019)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

The Role and Limitations of 18-Fluoro-2-deoxy-d-glucose Positron Emission Tomography (FDG-PET) Scan and Computerized Tomography (CT) in Restaging Patients with Hepatic Colorectal Metastases Following Neoadjuvant Chemotherapy: Comparison with Operative and Pathological Findings
por: Lubezky, Nir, et al.
Publicado: (2007)

First Results and Experience with PRRT in South Africa
por: Vorster, Mariza, et al.
Publicado: (2018)

PRRT2, a network stability gene
por: Michetti, Caterina, et al.
Publicado: (2017)

New Insights in PRRT: Lessons From 2021
por: Puliani, Giulia, et al.
Publicado: (2022)

(99m)Tc-MDP bone scintigraphy of the hand: comparing the use of novel cadmium zinc telluride (CZT) and routine NaI(Tl) detectors
por: Koulikov, Victoria, et al.
Publicado: (2015)

The advantage of 3D conformal treatment of lumbar spine metastases in comparison to traditional PA or AP-PA techniques: restoring an intermediate niche of therapeutic sophistication
por: Soyfer, Viacheslav, et al.
Publicado: (2013)

How Many Nights Are Really Needed to Diagnose Obstructive Sleep Apnea?
por: Abreu, Alexandre, et al.
Publicado: (2022)

Pencil beam scanning dosimetry for large animal irradiation
por: Lin, Liyong, et al.
Publicado: (2014)

Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation
por: Cohen, Dan, et al.
Publicado: (2021)

A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [(18)F]FDG PET-CT studies performed in oncologic patients
por: Cohen, Dan, et al.
Publicado: (2021)

Beyond Visual Assessment of Basal Ganglia Uptake: Can Automated Method and Pineal Body Uptake Assessment Improve Identification of Nigrostriatal Dysfunction on (18)F-DOPA PET/CT?
por: Hazut Krauthammer, Shir, et al.
Publicado: (2023)

PRRT2 Mutant Leads to Dysfunction of Glutamate Signaling
por: Li, Ming, et al.
Publicado: (2015)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

Paroxysmal Dyskinesias in a PRRT2 Mutation Carrier
por: Marano, Massimo, et al.
Publicado: (2018)

Neoadjuvant PRRT for advanced pNEN: an unusual highlander
por: Zanata, Isabella, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

Long-term prognostic factors for PRRT in neuroendocrine tumors
por: Trautwein, Nils Florian, et al.
Publicado: (2023)

Sex differences in gray matter volume: how many and how large are they really?
por: Sanchis-Segura, Carla, et al.
Publicado: (2019)

How many SARS-CoV-2 “viroporins” are really ion channels?
por: Harrison, Neil L., et al.
Publicado: (2022)

Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force
por: Stokke, Caroline, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hqeutfafh9pis255gkc5c3312l